Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-21T08:21:04.316Z Has data issue: false hasContentIssue false

P03-38 - Atypical Antipsychotics and Screening of Metabolic Effects

Published online by Cambridge University Press:  17 April 2020

J. Campos Mendes
Affiliation:
Departamento de Psiquiatria e Saúde Mental, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
J. Prata
Affiliation:
Departamento de Psiquiatria e Saúde Mental, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Despite a better overall tolerance as compared to classical antipsychotics, atypical antipsychotics are not devoid of side-effects, notably metabolic factors - weight gain, alteration of lipid and glucose profile - that increase the risk of cardiovascular disease, as well as a number of other adverse long-term health consequences. Psychiatrists need to be aware of the potential metabolic side effects of antipsychotic medication and include them in the risk/benefit assessment when planning a patient's treatment strategy. Implementation of the necessary screening assessments and referral for treatment of any physical illness is essential and baseline screening and regular follow-up monitoring is advised.

Type
Psychotic disorders / Schizophrenia
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.